Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pixium Vision
Paris, Ile-de-France, France
- Ownership
- Private
- Development stage
- Other
01
Overview
Pixium Vision's PRIMA system, a wireless sub-retinal implant, has demonstrated partial vision restoration in late-stage age-related macular degeneration patients in feasibility and pivotal trials; recent pivotal studies included 38 patients and support regulatory submission in Europe in 2024[1][3][5].
- Therapeutic areas
- Ophthalmology
- Modalities
- DeviceBioelectronic deviceImplantable device
- Industry
- Implantable Medical Devices
02
Partnerships
Stanford University (technology collaboration on PRIMA)[3]Vision Institute (spin-out and academic partnership)[1][2]
Beyond the preview
Go deeper on Pixium Vision.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pixium Vision.